Our team members are recognized leaders in the field — at Dana-Farber, throughout the region, and nationwide — with specialized expertise in cellular therapy quality (improvement, assurance, and control). In addition, our team members are experts in regulatory compliance topics unique to this field, including cellular therapy clinical trials, and novel cellular manufacturing regulations.
Olive J. Sturtevant, MHP, MT(ASCP)SBB, SLS, CQA (ASQ)
Administrative Director, Cell Manipulation Core Facility (CMCF)
Olive Sturtevant and her team provide leadership and regulatory direction for multiple cellular therapy programs at Dana-Farber, Brigham and Women's Hospital, and Boston Children's Hospital. Olive acts as both a resource and consultant on matters of clinical laboratory compliance; GMP and GTP cell and tissue manufacturing; and overall quality and regulatory topics that range from cellular therapy adverse events and quality improvement processes and metrics to regulatory compliance for early-phase novel cell therapy manufacturing.
Roger Richard, MT (AMT)
Senior QA Manager, Cell Therapies
Roger's expertise spans cellular therapy-related regulatory compliance and quality assurance, new product development, workflow processes, data analysis, documentation and training management, and information system qualification and implementation. He and his team are responsible for the clinical administration component of the Hematopoietic Stem Cell Transplantation Program's
Foundation for the Accreditation of Cellular Therapy (FACT) continued accreditation. Roger also works closely with clinical program leadership to ensure the successful operations of a robust quality management program in order to ensure compliance with regulatory standards.
Mary Ann Kelley, MT(ASCP)BB
QA Manager, Connell and O'Reilly Families Cell Manipulation Core Facility
Mary Ann Kelley provides the
Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) with direction and leadership in the development and implementation of quality programs to support regulatory and accreditation requirements. She is responsible for the oversight of quality measures for the Stem Cell Processing Laboratory, Novel Cell Therapy Laboratory, and Quality Control Laboratory. She also oversees policies and procedures for product testing and release; ensures that all processes have been approved and validated; and oversees departmental audits and assessments to ensure regulatory compliance.
Bethany King, CQA (ASQ)
Clinical Program Technical Manager
Bethany is responsible for the quality management for cellular therapy donor services and the marrow collection facility. This includes management of FACT accreditation for those areas,
National Marrow Donor Program (NMDP) quality assurance, performance metrics and analytics, standard operating procedures, and training and competency for donor services staff and those making donor eligibility and suitability determinations. She oversees the auditing and validation of marrow harvest procedures, and she works closely with the processing lab and apheresis facility to monitor ongoing product quality.
Deborah J. Liney, MBA, CHTC
QA Manager, Cell Therapies
Deborah is responsible for quality assurance activities related to continuous process improvement, continued FACT accreditation, and transplant workflow processes. Deborah is also responsible for the annual review of treatment plans and assists by facilitating the creation of new stand-of-care treatment plans. In addition to these responsibilities, Deborah is also responsible for providing QA oversight to the DFCI/BWH Cord Blood Collection Program, a partnership with the Carolinas Cord Blood Bank at Duke University.
Ann Wood (CMCF)
Gauravi Prabhu (CMCF)
Michelle Lynch (CMCF)
Shana Coyne (CMCF)
Andrea Wilson (CMCF)
Kristie Defalco (CT QA)
Jill Tierney (CT QA)
QA Regulatory Coordinator
Cord Blood Collection Technicians